Susan G. Komen Launches 2026 Shop for the Cure, Rallying Brands to Combat Breast Cancer Disparities

  • Susan G. Komen launched its 2026 Shop for the Cure program, uniting purpose-driven brands to fund breast cancer research and patient care.
  • The initiative aims to address rising breast cancer incidence among women under 50 and persistent disparities in Black and Hispanic/Latina communities.
  • Komen has invested over $1.1 billion in research and $2.7 billion in patient support, contributing to 31 of the last 32 FDA-approved breast cancer treatments.
  • Participating brands include Bank of America, J.Crew, Wacoal, and See’s Candies, offering products that fund Komen’s mission.

Susan G. Komen’s 2026 Shop for the Cure program reflects a strategic pivot toward collaborative fundraising amid rising breast cancer disparities. The initiative leverages corporate partnerships to address systemic barriers in patient care, particularly for underrepresented groups. With breast cancer deaths projected at over 42,000 in the U.S. this year, the program’s success hinges on scaling contributions from purpose-driven brands and consumers alike.

Partnership Scale
Whether the 2026 Shop for the Cure can sustain momentum given the rising incidence of breast cancer among younger women.
Disparity Reduction
The pace at which Komen’s initiatives can narrow the 40% higher mortality rate among Black women compared to white women.
Funding Impact
How the $1.1 billion research investment and $2.7 billion in patient support translate into tangible treatment breakthroughs.